← ANALYST RATINGS · TIPRANKS
Delcath Systems (DCTH): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $24.50, the highest $32.00, the lowest $21.00. The average is +74.0% from the last price of $14.08.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Medical - DevicesxAI Grok-3 | TipRanks - xAI | $18.00 → $16.50−8.3% | Buy | +17.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI DeepSeek Medical - DevicesDeepSeek R1-0528 | TipRanks - DeepSeek | $17.50 → $16.00−8.6% | Hold | +13.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI OpenAI Medical - DevicesOpenAI 4o | TipRanks - OpenAI | $18.00 → $16.50−8.3% | Buy | +17.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Anthropic Medical - DevicesAnthropic Opus-4.1 | TipRanks - Anthropic | $18.00 → $16.00−11.1% | Hold | +13.6% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI Google Medical - DevicesGemini 2.5Pro | TipRanks - Google | $18.50 → $16.50−10.8% | Buy | +17.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:05 | — | |
| AI PerPlexity Medical - DevicesPerPlexity SonarPro | TipRanks - PerPlexity | $18.00 → $16.50−8.3% | Buy | +17.2% | Upgrade | 17.10.26on TipRanks Oct 16 23:05 | — | |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $21.00 | Buy | +49.1% | Reiterated | 09.10.26on TipRanks Oct 12 09:45 | +1.5%next day +2.1% · 5 days −6.4% | ↗ |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $32.00 | Buy | +127.3% | Reiterated | 21.09.26on TipRanks Sep 22 05:35 | −1.6%next day +1.8% · 5 days −0.8% | ↗ |
| John Newman★★★★★★★★★★#3035 · hits 44% · avg +4.1% | Canaccord Genuity | $21.00 | Buy | +49.1% | Reiterated | 11.08.26on TipRanks Aug 12 07:25 | +3.6%next day −0.9% · 5 days −1.7% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $18.00 → $24.00+33.3% | Buy | +70.5% | Reiterated | 07.08.26on TipRanks 10:00 | −2.9%next day +10.4% · 5 days +10.3% | ↗ |
| Marie Thibault★★★★★★★★★★#12343 · hits 40% · avg −9.7% | BTIG | $16.00 → $17.00+6.2% | Buy | +20.7% | Reiterated | 13.07.26on TipRanks 07:46 | −0.3%next day +1.7% · 5 days −1.2% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $29.00 → $27.00−6.9% | Buy | +91.8% | Reiterated | 26.02.26on TipRanks 20:40 | −0.6%next day +0.3% · 5 days +4.0% | ↗ |
| Unknown Analyst | Stephens | $18.00 | Buy | +27.8% | Reiterated | 03.12.25on TipRanks 09:00 | +3.4%next day +3.7% · 5 days +2.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Delcath Systems
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $23.50 at a price of $15.97 (+47.2%); now: $24.50 at $14.08 (+74.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 5 | 4 | 4 | 3 |
| Buy | 4 | 3 | 2 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.09 (from $-0.13 to $-0.04). Last quarter: $0.07.
Sales
Next quarter’s sales estimate — $26M (from $25M to $27M). Last quarter: $29M.
Best top-analyst consensus in the sector · Healthcare
About Delcath Systems
- CEO: Gerard J. Michel
- Employees: 156
- 566 Queensbury Avenue, Queensbury, NY, 12804, US
- www.delcath.com
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Data from the stock’s TipRanks forecast page, read 124 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗